- Home
- APPS vs AMLX Comparison
APPS vs AMLX Comparison
Compare APPS & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APPS
- AMLX
- Stock Information
- Founded
- APPS 2007
- AMLX 2014
- Country
- APPS United States
- AMLX United States
- Employees
- APPS N/A
- AMLX N/A
- Industry
- APPS Multi-Sector Companies
- AMLX Biotechnology: Pharmaceutical Preparations
- Sector
- APPS Miscellaneous
- AMLX Health Care
- Exchange
- APPS Nasdaq
- AMLX Nasdaq
- Market Cap
- APPS 555.2M
- AMLX 459.1M
- IPO Year
- APPS N/A
- AMLX 2022
- Fundamental
- Price
- APPS $5.76
- AMLX $5.05
- Analyst Decision
- APPS Hold
- AMLX Buy
- Analyst Count
- APPS 3
- AMLX 6
- Target Price
- APPS $3.33
- AMLX $10.17
- AVG Volume (30 Days)
- APPS 9.7M
- AMLX 871.7K
- Earning Date
- APPS 06-16-2025
- AMLX 08-07-2025
- Dividend Yield
- APPS N/A
- AMLX N/A
- EPS Growth
- APPS N/A
- AMLX N/A
- EPS
- APPS N/A
- AMLX N/A
- Revenue
- APPS $490,506,000.00
- AMLX N/A
- Revenue This Year
- APPS $9.10
- AMLX N/A
- Revenue Next Year
- APPS $8.12
- AMLX N/A
- P/E Ratio
- APPS N/A
- AMLX N/A
- Revenue Growth
- APPS N/A
- AMLX N/A
- 52 Week Low
- APPS $1.18
- AMLX $1.62
- 52 Week High
- APPS $7.77
- AMLX $7.27
- Technical
- Relative Strength Index (RSI)
- APPS 56.32
- AMLX 48.04
- Support Level
- APPS $4.55
- AMLX $5.24
- Resistance Level
- APPS $5.46
- AMLX $5.66
- Average True Range (ATR)
- APPS 0.74
- AMLX 0.34
- MACD
- APPS 0.10
- AMLX -0.05
- Stochastic Oscillator
- APPS 44.34
- AMLX 21.97
About APPS Digital Turbine Inc.
Digital Turbine Inc is an independent mobile growth platform. It offers end-to-end products and solutions to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. Its operating segments are On Device Solutions and App Growth Platform.
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.